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B7-transfectant tubular epithelial cells induce T cell anergy, ignorance
or proliferation. We have previously established that interferon (IFN)-y
stimulated, antigen-pulsed tubular epithelial cells (TEC) stimulate anti-
gen (Ag) specific activation of T cell hybridomas to express IL-2, In
contrast, these Ag pulsed TEC do not stimulate T helper I (Thi) clones
to proliferate, but rather render them unresponsive, since Ag pulsed
spleen cells cannot restore these cells to proliferate. The interaction of
the T cell CD28 surface protein with its ligand B7 expressed on Ag
presenting cells bearing Ia is a potent co-stimulatory signal capable of
inducing T cell proliferation. Hence, the lack of 87 on TEC was
hypothesized to be responsible for anergy in these ThI cells. Therefore,
the B7 gene was transfected into a SV4O transformed TEC or Chinese
hamster ovary (CHO) cells, and created TEC and CHO cells expressing
surface B7 protein. TEC-B7 (IFN-y stimulated, Ag pulsed) express Ia
and induce IL.2 production by T cell hybridomas. In contrast, T cell
proliferation was not induced by TEC-B7 or CHO-B7 cells; however,
these Thi cells were not anergic since they could be stimulated to
proliferate to Ag pulsed spleen cells (immunological ignorance). How-
ever, co-cultivating TEC- B7 (IFN-y stimulated, Ag pulsed) with Thi
cells stimulated through the T cell receptor (TCR) using anti-CD3
monoclonal antibody (mAb) caused these Thl cells to proliferate.
Furthermore, anti-CD28 and anti-B7 mAbs blocked this response.
These data suggest that the spectrum of ThI cell activation after
encounter with Ag is dictated by: (I) the vigor of TCRJCD3 signal, and
(2) presence or absence of co-stimulatory signals through the CD28
pathway. Since expression of Ia on TEC induces anergy, this may serve
as a mechanism to thwart—not foster—autoimmunity.
Following the recognition of antigen (Ag) presented by major
histocompatibility complex (MHC) molecules on Ag presenting
cells (APC) by the T cell receptor (TCR), T cell activation
commences; however, stimulation of the TCR complex alone is
insufficient to induce full T cell activation. In order to stimulate
proliferation of unprimed T cells, a second (that is, costimula-
tory) signal provided by professional APCs is required [1—3].
The interaction of CD28/CTLA-4 on T cells and B7/BB 1 pro-
teins, which are expressed upon dendritic cells, activated B
cells and interferon-y (IFN-y) stimulated macrophages (MØ)
elects a powerful costimulatory signal [4-13]. For example,
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both bivalent anti-CD28 monoclonal antibody (mAb) and B7
fibroblast and mast cells transfected with B7 have been reported
to provide the costimulatory signal required to facilitate Ag-
stimulated T cell activation [14—20]. Monovalent anti-CD28
IgG/Fab mAb, anti-B7 mAb or a fusion protein consisting of the
extracellular domain of human CTLA-4 genetically linked to
human constant region IgGyl heavy chains (CTLA4Ig) inhibit
the human allogeneic mixed leukocyte culture (MLC) and T cell
dependent antibody production in both human and mouse
models [13, 21—241. Indeed, human MLC treated with CTLA4Ig
induces a state of Ag specific T cell hyporesponsiveness, that is,
anergy [24]. Clearly, the CD28/CTLA4 pathway is a major
costimulatory pathway for T cell activation.
Many investigators have noted the unusual expression of Ia
upon parenchymal epithelial cells, such as the thymus, small
intestine and target cells of various non-lymphoid tissues in
autoimmune diseases, and have speculated that increased Ia
expression may play an important role in the pathogenesis of
autoimmune tissue injury [25—30]. Over a decade ago Botazzo
proposed that Ia expression on target cells of autoimmune
diseases such as thyroid epithelial cells would result in presen-
tation of self-Ags to T cells and thereby promote or facilitate
autoimmune tissue injury [30]. However, some recent studies
have suggested that Ag presented by parenchymal Ia cells
("non-professional APCs") might induce mature peripheral T
cell clonal anergy/tolerance as a result of the inability of these
cells to deliver costimulatory signals required for T cell activa-
tion [25, 26]. For example, renal tubular epithelial cells (TEC)
can express Ia during allograft rejection, autoimmune renal
injury and graft versus host disease [27—29, 31, 32]. We have
determined that: (i) TEC clones can be induced to express both
I-A and I-E MHC-class II molecules following IFN-y stimula-
tion in vitro, and (ii) Ag-pulsed, Ia TEC stimulate Ag-specific
T cell hybridomas to secrete IL-2 [33]. Since T cell hybridomas
are more readily activated by Ag alone than normal T cells, we
designed studies to determine whether Ag pulsed, Ia TEC
could activate normal T cell clones. In contrast to the results
noted with Ag-specific T cell hybridoinas, Ag pulsed, Ia TEC
not only fail to activate IL-2 producing T cells, but renders
cloned IL-2 producing T cells anergic [34]. In addition, trans-
genic mice that express high levels of MHC-class II molecules
on TEC do not initiate autoimmune injury in a transplant model
[35]. Hence, we hypothesized that the failure of Ag pulsed Ia
TEC to deliver effective costimulatory signals was a result of
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the inability to express a costimulatory molecule such as the B7
ligand.
This report examines the ability of TECs transfected with
murine B7 encoding cDNA to provide costimulatory molecules
to mouse Thi clones in order to test this hypothesis. For this
purpose, we established mouse B7 TEC lines (TEC-B7), and
analyzed Ag pulsed, IFN-y stimulated (Ia)TECs for their
capacity to stimulate Thi clones to proliferate. Ag-pulsed,
IFN-'y stimulated TECs, but not TEC-B7, rendered cloned IL-2
producing T cells anergic. Hence, the presence or absence of
expression of B7 can determine whether TEC can induce
anergy. While Ag-pulsed, IFN-y stimulated TEC-B7 do not
stimulate the proliferation of cloned IL-2 producing T cells, if
the TCRs of IL-2 producing T cells are stimulated with both Ag
and anti-CD3 mAb these Thi clones proliferate. Hence, the
capacity of Ag pulsed, Ia epithelial cells expressing B7 to
stimulate T cell proliferation depends at least in part upon the
ability of epithetial cells to provide an intense signal through the
TCRICD3 complex. Clearly, the role of Ia parenchymal cells
in causing autoimmunity must be re-evaluated.
Methods
Mice
C3H/FeJ (H2k) female mice were purchased from The Jack-
son Laboratory (Bar Harbor, Maine, USA) and maintained in
our animal facility. Mice were used between 6 to 12 weeks of
age.
Cell clones
A.E7, a pigeon cytochrome c (amino acids 81-104)-specific,
IEkrestricted Thl cell clone, was provided by Dr. Abul Abbas
(Brigham and Women's Hospital, Boston, Massachusetts,
USA) [36, 37]. A2.A2, a subclone of the T cell hybridoma
A2.2B2 which recognizes hen egg lysozyme in the context of!-
A' [38], was provided by Dr. Laurie Glimcher (Harvard School
of Public Health, Boston, Massachusetts, USA), respectively.
HT-2 cells, an IL-2/!L-4-dependent cell line were provided by
Dr. Abul Abbas. CS3.1 is a renal TEC clone derived from
C3H/FeJ mice. The method of isolation has been previously
described [33, 34]. Briefly, TEC were prepared by collagenase
dispersion and sequential sieving of renal cortices. Cells were
subcloned by the limiting dilution technique after transforma-
tion with origin-defective SV4O DNA. These TEC have mor-
phologic and physiologic characteristics of proximal TEC and
can be stimulated by IFN-y to express Ia and enhance the level
of intercellular adhesion molecule-l (ICAM-l) on its surface.
B? transfected CS3.1 (TEC-B7) and Chinese hamster ovary
(CHO) (CHO-B7) cells
Murine B7 cDNA was subcloned into the pRC/CMV expres-
sion vector [12]. TEC and CHO cells were transfected with 20
g pRC/CMV/B7 plasmid by electroporation (1.5 KY, 30 pFD)
using a Gene Pulser (Bio-Rad Laboratories, Richmond, Califor-
nia, USA) and selected in culture medium (Ki medium, 1:1
mixture of Dulbecco's modified Eagle's medium (DMEM) and
Ham's F12, containing additives as described including 25
ng/ml of epidermal growth factor for TEC and RPMI164O +
10% FCS for CHO cell) supplemented with 1.5 mg/mI G4l8
(Gibco Laboratories, Grand Island, New York, USA). After
drug selection, transfectants were maintained in culture me-
dium containing 0.4 mg/mI G418.
Ag and reagents
Tissue culture media and reagents were purchased from
Gibco. Mitomycin C, hen egg lysozyme (HEL) and pigeon
cytochrome c (PCC) were purchased from Sigma Chemical Co.
(St. Louis, Missouri, USA). Monoclonal antibodies (mAb)
against IEk (clone 14.4.4S, American Type Culture Collection,
Rockville, Maryland, USA) and the murine CD3-€ chain (clone
145.2Cll provided by Dr. Jeffrey Bluestone, University of
Chicago, Chicago, Illinois, USA) were obtained by affinity
purification of supernatants over protein A-Sepharose CL-4B
columns (Pharmacia, Piscataway, New Jersey, USA). Hamster
anti-murine B7 mAb (clone 16-lOAl) [13] was provided by Dr.
Hans Reiser (Dana-Farber Cancer Institute, Boston, Massachu-
setts, USA). Purified hamster anti-murine CD28 (clone 37.51)
[14, 15] and mouse anti-murine IAk (clone 11-5.2) mAbs were
purchased from Pharmingen (San Diego, California, USA).
Murine recombinant IFN-y was a gift from Genentech (San
Francisco, California, USA). Murine recombinant IL-2 was
purchased from Genzyme (Cambrige, Massachusetts, USA).
Fluorescence cytometry
Subconfluent monolayers of TEC were cultured for 72 hours
in modified Ki medium with or without IFN-y (100 U/mI). Cells
were harvested by trypsinization, and resuspended at 5 x l0 to
1 x 10 cells/mi in PBS with 3% FBS/0.l% NaN3. Cells were
analyzed for the surface expression of B7, 1Ak and I-E" using
hamster anti-murine B7 mAb (16-1OA1), mouse antiIAk mAb
(11-5.2) and mouse antiIEk mAb (l4.4.4S) followed by FITC-
conjugated anti-hamster or mouse IgG/goat IgG F(ab')2 anti-
bodies (Cappel, West Chester, Pennsylvania, USA) before
being analyzed by a FACscan Flow Cytometer (Becton Dick-
inson, Mountain View, California, USA). We analyzed 5,000
cells per sample. Rat IgG and mouse IgG were used as a
negative control.
Induction of T cell anergy
A.E7 cells (7 x 105/well) were preincubated in 2.0 ml medium
in 24-well plates with or without Ag, with I x 106 mitomycin C
treated (100 g/ml x 1 hr at 37°C) TEC, mitomycin C-treated
TEC-B7, mitomycin C treated IFN-y stimulated TEC or mito-
mycin C treated IFN-y stimulated TEC-B7. A.E7 cells were
also cultured in medium alone, antigen pulsed irradiated (1500
R) syngeneic splenocytes or on anti-CD3 mAb-coated wells as
controls. After 24 hours of culture, T cells recovered on
Ficoll-Hypaque (Cedarlane Laboratory Ltd., Hornby, Ontario,
Canada) density gradients and were rested for 48 to 72 hours
prior to culture for three days in 96-well microtiter plates (2 to
3 X i0 cells/well) with 5 x l0 irradiated syngeneic splenocytes
and Ag or with IL-2 alone. Proliferation and IL-2 response were
assayed as described below.
Thi cell clone proliferation assay
All cultures were performed in RPM! 1640 supplemented
with 10% fetal bovine serum (FBS) (HyClone, Logan, Utah,
USA), 50 tM 2-ME, 10 mrvi HEPES, 1 mivi Na pyruvate, 0.1
m non-essential amino acids, and antibiotics. Two to 3 x iO
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A.E7 T cells Irrad APC+Ag CD28 B7
A.E7 cells were cultured in anti-CD3 mAb-coated or non-
coated 96-well flat-bottom microtiter plates (Falcon, Lincoln
Park, New Jersey, USA) in 0.2 ml of medium with one of four
types of stimulator cells: 5 x i0 1% paraformaldehyde treated
CHO cells, CHO-B7, mitomycin C treated TEC, or TEC-B7.
A.E7 cells were also cultured with 5 x io Ag pulsed mitomycin
C treated TEC-B7 or mitomycin C treated IFN-y stimulated
TEC-B7. As an Ag specific positive control, 5 x i0 irradiated
splenic APC were cultured with varying doses of Ag. After
three days of culture, wells were pulsed with 1 sCi of tritiated
thymidine (3H-TdR, 6.7 mCi/mM; New England Nuclear, Bos-
ton, Massachusetts, USA) and harvested six hours later using a
PHD cell harvester (Cambridge Technology Inc., Cambridge,
Massachusetts). Thymidine incorporation was quantitated by
liquid scintillation counting. Determinations were performed in
triplicate. Background proliferation (without Ag) was < 1,000
cpm. Blocking experiments using anti-CD28 (37.51)and anti-B7
(16. 1OAI) mAb was included in each experiment. Hamster IgG
served as controls.
T cell hybridoma response and IL-2 assay
The response of A2A2 T cell hybridoma cells was evaluated
by measuring IL-2 production for 24 hour stimulation with
various doses of HEL. We assayed IL-2 by determining the
ability of culture supernatants to support the growth of 2 x iO
HT-2 cells. After 24 hours co-culture, each well was pulsed with
1 pCi of 3H TdR, and harvested these cultures six hours later
and quantitated thymidine incorporation as described above.
As a positive control, we cultured HT-2 cells with serial
dilutions of murine recombinant IL-2.
Results
Anti-mouse CD28 and B7 mAbs block Ag presentation by
splenic AFC
In previous experiments, we first noted that cloned A.E7 ThI
cells proliferate when cultured with irradiated syngeneic splenic
APC and Ag, but do not respond to Ag pulsed IFN-y treated
(Ia) TEC (data not shown). Since B7 has been shown to
provide a costimulatory signal to resting T cells by binding to
cell surface CD28/CTLA4 proteins, we examined the potential
involvement of the CD28-B7 pathway in A.E7 Thi cell activa-
tion. As compared with A.E7 Thi cells and irradiated syngeneic
splenic APC and Ag alone, the proliferation of A.E7 Thl cells
Fig. 1. Anti-mouse CD28 and B7 mAb block
Ag presentation by splenic APCs. A. E7 cell
proliferation was assayed by measuring
incorporation of tritiated thymidine for last 6
hr of 3 days culture in triplicate, and is
expressed as X SEM of three experiments.
A final concentration of 10 pg/mI of each mAb
was added at the onset of culture. Inhibition
by anti-CD28 (37.51) and anti-B7 (16—10A1)
mAbs ranged from 97 to 99% and 56 to 93%,
respectively. In these assays 2.5 x io A.E7
cells was used and a fixed number of
irradiated (1500 R) splenic APC.
was blocked by the addition of either anti-B7 or anti-CD28 mAb
to cultures (Fig. 1). These data suggested that A.E7 cloned Thi
cells receive crucial costimulatory signal(s) via the CD28-B7
interaction.
A.E7 Thi cells are rendered anergic by IFN-y treated TEC
pulsed with Ag or with anti-CD3 mAb
Engagement of the TCR without appropriate costimulatory
signals results in Ag-specific unresponsiveness, or anergy.
Anergic T cells fail to secrete IL-2 or proliferate when restim-
ulated with Ag pulsed APCs. However, anergic cells can
proliferate in response to IL-2. Therefore, the primary stimu-
lation consisted of A.E7 cells co-cultured with IFN-y stimu-
lated (Ia) or unstimulated (1a) TEC. In these experiments
A.E7 cells were incubated with or without specific Ag, and
stimulated or not stimulated with anti-CD3 mAb. In a second-
ary stimulation A.E7 cells were co-cultured with either irradi-
ated spleen APC and Ag or IL-2 (Table 1). A.E7 Thl cells
cocultured with TEC stimulated with IFN-y and pulsed with Ag
proliferated less vigorously in response to irradiated splenic
APC pulsed with Ag as compared with A.E7 Thi cells cocul-
tured with IFN-y stimulated TEC without Ag, TEC with or
without Ag, or media alone. A.E7 Thi cells prestimulated with
anti-CD3 mAb proliferated less briskly to irradiated splenic
APC pulsed with Ag as compared with irradiated splenic APC
pulsed with Ag alone (Table 1 represents 1 out of 3 represen-
tative experiments). Following each of these culture conditions,
A.E7 ThI cells remained viable as established by their respon-
siveness to IL-2 (Table 1). Thus, A.E7 cells pre-cultured with
Ag pulsed IFN-y stimulated-TEC or stimulated with anti-CD3
mAb were rendered anergic.
TEC-B7 cell lines express the B? ligand and can be
stimulated with IFN-y to Induce I-A" and I-E" determinants
Using flow cytometric analysis we detected both I-A" and
I-E" expression on TEC following stimulation with IFN-y
(Fig.2). However, TEC with and without stimulation with
IFN-ydid not express B7 on the cell surface (Fig. 2). To further
define the role of CD28/CTLA4 costimulation in T cell anergy
induced by TEC, we transfected the mouse B7 encoding cDNA
into TEC and CHO cells. CHO cells were studied in parallel to
TEC, since they do not express any known costimulatory
+ +
+
+
+ + —
+ — +
0 10 20 30
A.E7 cell proliferation, cpm, x103
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Table 1. A.E7 cloned Thi cells were rendered anergic by either
stimulation with IFN-y treated TEC pulsed with Ag or with anti-CD3
mAB
Protocol
Primary stimulation Secondary stimulation
irrad
Stimulants APC +
Ag" (cpm IL2eA,E7
cells aCD3c Cell type IFNya Agb x l0) (cpm x 10)
+ — TEC — — 12.5 3.1 117 1,2
+ — TEC — + 12.4 1.3 81 0.8
+ — TEC + — 11.0±0.6 79±0.8
+ — TEC + + 3.9 0.4 91 0.9
+ — irrad APC — + 12.0 0.3 105 1.1
+ + — — — 0.4 0.1 122 1.1
+ — — — — 14.1 2.3 117 1.1
a IFN-y 100 U/mi for 72 hrb PCC 100 g/m1
C Coated with 10 pg/mi of mAb for 2 hrd Ag specific response: irradiated splenic APC with PCC 0, 10, 30 and
100 g/ml for 72 hr and 3H-TdR uptake after 6 hr culture. Data above for
PCC 100 g/ml; the pattern of response was similar at two lower
concentrations, PCC 10 and 30 g/m1. Values = X SD in triplicate.
e A.E7 cell response to IL-2: cultured with IL-2 (25 U/mi) for 48 hr
and 3H-TdR uptake after 6 hr culture in triplicate. Values = X SD in
triplicate.
molecules. Following transfection TEC and CHO cells ex-
pressed B7 as determined by fluorocytometic analysis (2 to 10%
and 1 to 2%, respectively; Fig. 2). Surface expression of B7
molecules on TEC-B7 was also detectable by immunoperoxi-
dase technique using rat anti-mouse B7 mAb. After transfection
with B7 cDNA, it was established that TEC-B7 retained the
capacity to be induced by IFN-y and express both lAk and I-E"
determinants (Fig. 2).
B7 ligand expression on TEC does not provide a sufficient
signal to induce A.E7 Thi cell proliferation, but does prevent
anergy
Previously, we reported that in response to Ag pulsed Ia
TEC, T cell hybridomas produce IL-2, while A.E7 Thi cells do
not proliferate and are in fact rendered anergic [34]. Therefore,
we examined the capacity of Ia TEC-B7 to present Ag to the
A2A2 T cell hybndoma and A.E7 Thi cells. Ag pulsed Ia
TEC-B7 cells induced Ag-dependent IL-2 production by the
A2A2 T cell hybridoma as detected by the HT-2 indicator line,
but failed to stimulate A.E7 Thi cells to proliferate (Fig. 3 A, B
respectively). A.E 7 cells were not rendered anergic by Ag pulsed
Ia TEC-B7, since they were cabale of proliferating in a second-
ary culture to irradiated splenic APC pulsed with Ag (Table 2).
Thus, A.E7 cells cultured with Ia TEC-B7 with Ag behave as
if they had never encountered Ag (immunological ignorance),
that is, they did not proliferate nor were they rendered anergic.
A.E7 Thi cells required anti-CD3 mAb stimulation for
TEC-B7 or CHO-B7 cells to confer proliferation
To determine whether cells transfected with B7 could provide
a costimulatory signal, we co-cultured A.E7 Thl cells with
either TEC-B7 with or without IFN-y stimulation or CHO-B7
cells. These B7 transfected TEC and CHO cells were compared
with untransfected cells similarly prepared. To prevent the
stimulator cells from dividing, the TEC and TEC-B7 were
incubated with mitomycin C and the CHO and CHO-B7 cells
fixed with paraformaldehyde. These cells were cocultured in
plates coated with varying concentration of anti-CD3 mAb.
Anti-CD3 mAb alone at a dose of 0.1 to 10 g/ml did not
stimulate A.E7 Thl cells to proliferate; however, the addition of
10 p.g/ml of anti-CD3 mAb to cultures also containing TEC-B7
or CHO-B7 stimulated A.E7 Thl cells to proliferate. By com-
parison, CHO cells and TEC did not stimulate A.E7 Thl cells to
proliferate in the presence or absence of anti-CD3 mAb (Fig. 4).
The proliferative response of A.E7 Thi cell to TEC-B7 stimu-
lated with anti-CD3 mAb was not altered by incubating TEC-B7
with IFN-y (data not shown). Furthermore, the proliferation of
A.E7 Thl cells stimulated with anti-CD3 mAb and TEC-B7
requires the B7/CD28 ligand interaction, since both anti-B7 and
anti-CD28 mAbs inhibited the A.E7 cell proliferation (Table 3).
Given the paucity of cells expressing the B7 ligand, it was
concluded that only a few B7 transfected cells were required to
provide a sufficient costimulatory signal for A.E7 Thl cells
pre-stimulated via its TCR to proliferate.
Discussion
In theory, the attributes of stimulated TEC suggest that they
might support APC-like activities [39—47]. Following cytokine
stimulation, TEC can secrete a variety of molecules, including
tumor necrosis factor-a, IL-6, IL-8, transforming growth factor
(TGF)-f3, GM-CSF, MCP-1 and PDGF-p, and express cell
surface molecules such as MHC-class land class II, ICAM-l or
VCAM-l. Indeed, IFN-stimulated TEC expressing Ia can pro-
cess and effectively present Ag to T cell hybridomas which are
Ag specific and MHC restricted. T cell hybridomas can be
readily activated through stimulation of the TCR alone to
secrete IL-2. In fact, T cell hybridomas exposed to Ia bound Ag
on a planar lipid membrane can be stimulated to release IL-2
[48]. However, T cell clones require a costimulatory signal
(second signal) as well as a first signal delivered to the TCR
either via (i) engagement with a specific Ag within the groove of
the Ia molecule, or (ii) crosslinking mAb [2, 49—52]. Although
IFN-y treated, Ag pulsed TEC stimulate T cell hybridomas, our
previous experiments revealed that Ag pulsed, IFN-y activated
TEC not only fail to activate Thi clones, but they induced Ag
specific unresponsiveness, that is, anergy, in these cloned Thl
cells [34]. These results suggest that TEC fail to provide
effective costimulatory signals that are required to support the
activation of Thi cells.
Recently, a uniquely powerful costimulatory pathway has
been defined involving the protein to protein interaction of
CD28/CTLA4 on T cells with B7 upon APCs. This pathway
utilizes a Ca2 protein kinase C independent signaling pathway
that is completely distinct from the signaling pathway initiated
by TCR stimulation [4, 5, 8, 9]. Dendritic cells constitutively
express the B? molecule. B7 is also expressed on activated, but
not resting B cells or MØ [11—13, 22]. While IFN-y stimulated
MØ are induced to express B7, TEC do not express the B7
ligand following IFN-y treatment (Fig. 2). TEC-B7, but not
CHO-B7 transfectants, secrete and express membrane bound
cytokines. Since TEC-B7 and CHO-B7 cells co-cultured with
A.E7 Thl cells stimulated with anti-CD3 mAb proliferate, we
have established that B7 alone can confer a sufficient second
signal to A.E7 Thl cells. While TEC-B7 can process and
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present Ag, CHO cells cannot present Ag to Thi cells. Hence,
the ability of CHO-B7 transfectants to provide costimuli, which
Ag pulsed, Ia cells cannot provide, demonstrates that there is
no requirement for the TCRJCD3 complex and CD28/CTLA4
proteins to cocluster in order to support T cell activation.
Clearly, A.E7 Thl cells receive a powerful costimulatory signal
from the B7 ligand expressed on APCs and B7 transfectants.
B7 can interact with two different molecules expressed on T
cells: CD28 and CTLA-4 [18, 23]. Therefore, it was important to
establish whether cells expressing B7 delivered a T cell activat-
ing signal via the CD28 or CTLA4 ligand. We determined that
Ag specific mouse Th 1 cells received a potent costimulatory
signal via its CD28 since blocking access of B7 to CD28 proteins
with anti-murine CD28 mAb prevented T cell proliferation.
Depending upon the experimental conditions anti-CD28 mAb
can either activate or block CD4+ T cell activation. Costimu-
lation requires exposure to bivalent mAb, however, in some
situations either monovalent or bivalent anti-human CD28 mAb
(clone 9.3 and L293) can block the costimulatory signal enabling
Ag specific human T cell activation, such as in a mixed
lymphocyte culture (MLC) or as induced by B7 transfectants
(Fig.!, Table 3). The same phenomena were reported in sys-
tems using mouse splenic T cell and cloned Thl cell prolifera-
tion assays [2, 3]. Therefore, it is possible that the extent of
cross linking of CD28 molecules may determine whether the
stimulatory or inhibitory effects are caused by treatment with
anti-CD28 mAb [6, 16]. When we exposed A.E7 Thi cells to
irradiated splenic APC pulsed with Ag and added anti-CD28
mAb the Thl cells were rendered anergic (data not shown).
These results are similar to the "anergizing" effects produced
by the CTLA-41g fusion protein, which binds to B7 ligand on
APCs [24]. In any event, our results highlight the important
costimulating role in the CD28-B7 interaction upon the Ag
specific response of mouse Thl clones.
In vitro, both the lack of a second signal and the intensity of
the first signal, as described below, are important factors for
determining whether T cell activation or anergy ensue, since T
cells interacted with chemically modified Ag pulsed [49, 50]
APC or either Con A or immobilized anti- CD3 mAb in the
absence of APCs [53, 54] were rendered anergic. Following
culture of T cells with functioning APC and certain non-
stimulatory peptide analogues of a specific Ag, anergy is also
Fig. 2. TEC-B7 cell express the B7 ligand,
stimulation with IFN-y induces IA-° and I-E"
determinants. Cells were incubated with
either medium alone or with hamster anti-
mouse B7 mAb (16-bAt), mouse anti-mouse
IAk mAb (11-5.2) or mouse anti-mouse IEk
niAb (14,4.4S), followed by FITC-conjugated
anti-hamster or mouse IgG/goat IgG F(ab')
antibodies (Cappel) before flow cytometric
analysis with a FACscan Flow Cytometer
(Becton Dickinson). We analyzed 5,000 cells
per sample. 87 was not expressed by TEC
after 72 hour culture with IFN-y of 100 U/mI,
while 9.7 to 2.4% of transfected TEC-B7 cells
expressed B7. IAk and IEk determinants
were induced by 42 to 47% and 16 to 30% of
TEC-B7 cells, respectively, following IFN-y
stimulation.
b o 4o o o io
Pigeon cytochrome c, 4ug/mI
Fig. 3. Ag pulsed IFN-y stimulated TEC-B7 can stimulate the A2A2 T
cell hybridoma, but not A.E7 Thi cells. (A) b0 A2A2 cells were
cultured for 24 hours with 5 X I O of mitomycin C-treated unstimulated
TEC-B7, or IFN-y stimulated TEC-B7 with various doses of Ag (HEL),
and their IL-2 production was assayed by biossay via IL-2 sensitive
HT-2 cell proliferation. (B) Four x b0 of A.E7 cells were cultured for
3 days with 5 x l0 of mitomycin C-treated unstimulated TEC-B7, or
IFN-y stimulated TEC-B7. As an Ag specific positive control, 5 x 10°
irradiated syngeneic splenic APCs were cultured with varying doses of
Ag. A.E7 and HT-2 cell proliferation was measured by tritiated thymi-
dine incorporation in triplicate, and is expressed as X SEM of three
experiments.
1-A' B7
20:
1 TEC
10° 101 102 10° 10° 101 102 10° 10° 101 102 10°
200 200 350
___ J JA j TEC B7
10° 101 102 10° 10° 101 102 10° 10° 101 102 10°
A
1000
100
10
1
0.1
Hen egg lysozyme, pg/mi
0 1 10
B
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1
0.1
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A.E7Tcells + +
Anti-CD3 +
Other cells TEC-B7 TEC CHO-B7
Table 2. B7 transfection into TEC protected A.E7 cloned Thi cells
from becoming anergic
Protocol
Primary stimulation Secondary stimulation
irrad
A.E7 cells
Stimulants APC +
Ag" (cpm
x l0) IL-2(cpm x 10)aCD3c Cell type IFN- Agb
+ — TEC + — 12.7 1.3 39 0,3
+ — TEC + + 3.2 0.4 46 0.3
+ — TEC-B7 + — 9.2 1.1 38 0.2
+ — TEC-B7 + + 8.3 1.2 42 0.3
+ + — — — 1.9 0.5 52 0.4
+ — — — — 10.6 1.3 51 0.3
a IFN-y 100 U/mI for 72 hrb PCC 100 1g/mi
Coated with 10 /ml of mAb for 2 hr
d Ag specific response: irradiated splenic APC with PCC 0, 10, 30 and
100 g/ml for 72 hr and 3H-TdR uptake after 6 hr culture. Data above for
PCC 100 /ml; the pattern of response was similar at two lower
concentrations, PCC 10 and 30 g/ml. Values = X SD in triplicate.
e A.E7 cell response to IL-2: cultured with IL-2 (25 U/mI) for 48 hr
and 3H-TdR uptake after 6 hr culture in triplicate. Values = X SD in
triplicate.
induced. Use of non-stimulating mutant peptides to confer a
modified first signal (a partial first signal), even in the presence
of a powerful costimulatory stimulant causes T cell anergy
rather than clonal expansion [55]. The exact mechanism by
which T cell anergy is induced by Ag pulsed "non-profession-
al" APCs such as TEC or thymic cortical epithelial cells is
unknown [25]. For example, in our previous studies we failed to
stimulate Thi clones by Ag pulsed, Ia TEC cocultured with
either allogeneic peritoneal exudate cells or splenocytes [34].
Taken together, these results suggest one of several posibilities:
(i) Ag pulsed, Ia TEC can only transmit a partial first signal to
Fig. 4. TEC-B7 and CHO-B7 abilily to induce
A.E7 Thi cell proliferation requires A.E7 cell
stimulation with anti-CD3 mAb. Two to 3 x
io A.E7 cloned Thl cells were cultured in
anti-CD3 mAb-coated or non-coated 96-well
flat- bottom microtiter plates in 0,2 ml of
medium. Four cell lines were tested for
costimulator cell activity; 5 x io of
mitomycin C-treated TEC-B7, mitomycin C-
treated TEC, 1% paraformaldehyde treated
CHO-B7, or 1% paraformaldehyde treated
CHO. A.E7 cell proliferation was analyzed by
a tritiated thymidine incorporation assay at
last 6 hours after 72 hour culture in triplicate.
This figure displays data selected from one
representative experiment out of three.
Variations of each value were always within
+ 15% of X values. A.E7 cell proliferation was
+
induced by both fixed CHO-B7 and mitomycin
C treated TEC-B7 cells, but not by CHO nor
CHO TEC.
Table 3. A.E7 Thi cell proliferation induced by stimulation with
anti-CD3 mAb and TEC-B7 is blocked by anti-B7 or anti-CD28 mAb
Cells mAb % Inhibition
(range)' NA.E7 cells TEC-B7 CD3 B7 CD28
+ + -I- + — 93
(89—98)
4
+ + + — + 89
(88-90)
2
a Anti-CD3 mAb coated with 10 ig/ml for 2 hr and TEC-B7 in
triplicate for 72 hr and pulsed 1 Ci of 3H-TdR for final 6 hr, mean
(controls) = 13 X io cpm (N = 4).b % Inhibition of A.E7 cell proliferation by each antibody (10 tg/ml)
was calculated as follows; 3H-TdR uptake with mAb (cpm) = uptake of
control (cpm)/uptake of control (cpm) x 100 (%).
T cells that result in anergy; (ii) Ag pulsed, Ia TEC can
provide the full first signal, but there is insufficient B7 expres-
sion to provide costimulation; (iii) both the first and second
signals induced by Ag pulsed, Ia TEC are suboptimal for
induction of T cell activation. To examine these points, B7 was
transfected into SV4O transformed proximal TEC (CS3. 1) and
CHO cells. It becomes clear that a small population of B7
transfectants among Ag pulsed, Ia TEC prevent Thl cells
from being rendered anergic since fewer than 10% of the
TEC-B7 population actually express detectable B7 molecules.
Expression of B7 by "non-professional" APCs (TEC5) abol-
ishes the capacity of such cells to induce anergy. Our results are
in keeping with demonstration that in B7 transfected tumor cells
are highly immunogenic [56, 57]. These results suggest that the
first signal provided by Ag pulsed, Ia TEC is stronger than the
signal induced by the non-stimulatory mutant peptide analogues
that cause anergy, since APCs pulsed with these peptides
render Thi clones anergic even if accompanied by an adequate
second signal(s).
2O
10
C.)
N-
w
0
+
+
+
+
+
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Although Ag pulsed Ia and B7 TEC stimulate IL-2 pro-
duction by T cell hybridomas, Thl clones cocultured with Ag
pulsed, Ia" TEC-B7 act as if they are immunologically ignorant,
since these Thi cells neither proliferate nor are the Thi cells
rendered anergic. Since TEC-B7 cells can provide costimula-
tion, the failure to stimulate T cells with TEC-B7 probably
resides with a quantitative or qualitative defect in Ag presenta-
tion. Our results give further insight into the implications of La
expression and Ag presentation by "non-professional APCs."
In vivo expression of MHC-class II on TEC may serve to
prevent or limit CD4-T cell-mediated immune injury during
autoimmune attack. Therefore, the role of Ia in autoimmune
tissue injury is complex and the outcome (T cell anergy,
ignorance or proliferation) is dependent on the presence or
absence of costimulation by surface molecules on TEC as well
as the intensity of signal delivered to the TCR complex.
In conclusion, these studies indicate: (1) a far weaker anti-
genic signal can induce T cell anergy as compared to the
intensity of the signal required to cause T cell proliferation. In
this regard, our data are similar to the results with mutant Ag
peptide pulsed APCs insofar as these cells do not promote T cell
proliferation, but render T cells anergic [55]. (ii) B7 expression
provides a costimulatory signal, even a numerically small
subset of B7 expressing cells can break anergy [7, 56, 57]. Thus,
both a strong antigenic signal plus a costimulatory signal are
required to induce Thi cell proliferation. Taken together,
parenchymal epithelial cells may be ideally suited to induce
anergy and protect from autoimmune tissue damage, since they
lack expression of the B7 ligand and provide only weak anti-
genic stimulation. It is likely that Ia expression provides a
vehicle to inhibit, not stimulate, autoimmunity.
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